Drug intelligence / Profile preview

diazepam + biperiden + droperidol + atropine sulfate

Development stage: Unknown
Lead developer: Roche
Modality: Small Molecules
Administration: Intravenous, Intramuscular

Overview

A combination medication containing diazepam (a benzodiazepine), biperiden (an anticholinergic), droperidol (a butyrophenone derivative and dopamine antagonist), and atropine sulfate (a muscarinic antagonist). This combination likely provides sedative, anticonvulsant, anticholinergic, and antiemetic effects. Diazepam enhances GABA inhibitory effects, biperiden treats extrapyramidal symptoms, droperidol produces tranquilization and prevents nausea, while atropine blocks muscarinic effects.

Targets

GABRR (GABA-A receptor subunit rho)DRD2 (Dopamine D2 Receptor)M1 (Muscarinic acetylcholine receptor M1)

Beyond the preview

Go deeper on diazepam + biperiden + droperidol + atropine sulfate.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on diazepam + biperiden + droperidol + atropine sulfate.

Explore the full profile